구조모아 (StructureMoa)항암 chemical structure spider web
방문분석
큐레이션 브리핑
경쟁 포지션: Monthly dosing and a finite course versus Leqembi's biweekly, open-ended schedule.
기전. Binds the N3pG epitope present in deposited plaque and drives microglial phagocytic clearance, converting amyloid-PET-positive patients to negative within months.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
N3pG amyloid-beta plaque
Early symptomatic Alzheimer's disease with confirmed amyloid pathology
US, JP
Approved
kisunla · donanemab · Kisunla · LY3002813 · donanemab-azbt
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG1 monoclonal antibody
Binds N-terminal pyroglutamate-3 modified amyloid-beta, a plaque-specific epitope
Plaque-only specificity permits aggressive clearance and pre-specified treatment discontinuation once amyloid PET turns negative.
구조화 데이터
Plaque-only specificity permits aggressive clearance and pre-specified treatment discontinuation once amyloid PET turns negative.
High baseline tau burden limits clinical benefit despite full plaque clearance.
Humanized IgG1 monoclonal antibody
N3pG amyloid-beta plaque · Amyloid PET centiloid, plasma p-tau217; baseline tau PET stratifies benefit.
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Monthly dosing and a finite course versus Leqembi's biweekly, open-ended schedule.
MCI or mild dementia due to Alzheimer's disease with amyloid confirmed by PET or CSF
First disease-modifying therapy
IV infusion
q4w with modified titration; stop after confirmed plaque clearance
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Monthly dosing and a finite course versus Leqembi's biweekly, open-ended schedule.
Binds the N3pG epitope present in deposited plaque and drives microglial phagocytic clearance, converting amyloid-PET-positive patients to negative within months.
Microglial Fc-mediated plaque removal.
Amyloid PET centiloid, plasma p-tau217; baseline tau PET stratifies benefit.
High baseline tau burden limits clinical benefit despite full plaque clearance.
구조화 데이터
Human
~12 days
Amyloid PET clearance rate, plasma p-tau217, iADRS/CDR-SB slope
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (early symptomatic AD)
APPROVAL · 2024년 7월
Modified titration label update to reduce ARIA-E
APPROVAL · 2025년 7월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.
분석
큐레이션 브리핑
경쟁 포지션: Monthly dosing and a finite course versus Leqembi's biweekly, open-ended schedule.
기전. Binds the N3pG epitope present in deposited plaque and drives microglial phagocytic clearance, converting amyloid-PET-positive patients to negative within months.
우선 정리한 핵심 프로그램입니다. 공개 출처가 있는 필드만 표시합니다.
구조화 데이터
N3pG amyloid-beta plaque
Early symptomatic Alzheimer's disease with confirmed amyloid pathology
US, JP
Approved
kisunla · donanemab · Kisunla · LY3002813 · donanemab-azbt
2026-09-10
Data Confidence · High
Development Signal · Established
Humanized IgG1 monoclonal antibody
Binds N-terminal pyroglutamate-3 modified amyloid-beta, a plaque-specific epitope
Plaque-only specificity permits aggressive clearance and pre-specified treatment discontinuation once amyloid PET turns negative.
구조화 데이터
Plaque-only specificity permits aggressive clearance and pre-specified treatment discontinuation once amyloid PET turns negative.
High baseline tau burden limits clinical benefit despite full plaque clearance.
Humanized IgG1 monoclonal antibody
N3pG amyloid-beta plaque · Amyloid PET centiloid, plasma p-tau217; baseline tau PET stratifies benefit.
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Monthly dosing and a finite course versus Leqembi's biweekly, open-ended schedule.
MCI or mild dementia due to Alzheimer's disease with amyloid confirmed by PET or CSF
First disease-modifying therapy
IV infusion
q4w with modified titration; stop after confirmed plaque clearance
ARIA surveillance with MRI; ApoE ε4 genotyping before treatment
Monthly dosing and a finite course versus Leqembi's biweekly, open-ended schedule.
Binds the N3pG epitope present in deposited plaque and drives microglial phagocytic clearance, converting amyloid-PET-positive patients to negative within months.
Microglial Fc-mediated plaque removal.
Amyloid PET centiloid, plasma p-tau217; baseline tau PET stratifies benefit.
High baseline tau burden limits clinical benefit despite full plaque clearance.
구조화 데이터
Human
~12 days
Amyloid PET clearance rate, plasma p-tau217, iADRS/CDR-SB slope
구조화 데이터
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다. 효능 수치는 선택한 등록 결과이며 전적응증 값이 아닙니다.
FDA approval (early symptomatic AD)
APPROVAL · 2024년 7월
Modified titration label update to reduce ARIA-E
APPROVAL · 2025년 7월
바이오정보모아는 연구·교육용 과학·의약품 개발 정보입니다. 진료, 진단, 치료 지침, 규제 자문이 아닙니다.